ArticleJournal of personalized medicine2022
Validation of a Novel Three-Dimensional (
Abstract read
In one paragraph
Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Application of three-dimensional reconstruction combined with enhanced recovery after surgery in patients undergoing laparoscopic partial nephrectomy: a prospective observational study.BMC nephrology · 2026Observational
- Multiphase comparative study for WHO/ISUP nuclear grading diagnostic model based on enhanced CT images of clear cell renal cell carcinoma.Scientific reports · 2024Article
- Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).Future oncology (London, England) · 2024Article
- Primary squamous cell carcinoma with sarcomatoid differentiation of the kidney associated with ureteral stone obstruction: A case report.World journal of clinical cases · 2022Article
- Article
- Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems.Journal of personalized medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
76 authors.
Matteo BrunelliPathology Unit, Department of Diagnostics and Public Health, University and Hospital Trust of Verona, 37134 Verona, Italy.
Guido MartignoniPathology Unit, Department of Diagnostics and Public Health, University and Hospital Trust of Verona, 37134 Verona, Italy.
Giorgio MalpeliDepartment of Surgery, Dentistry, Paediatrics and Gynaecology, University of Verona, 37134 Verona, Italy.ORCID 0000-0002-2996-2903
Alessandro VolpeDivision of Urology, Maggiore della Carità Hospital, 28100 Novara, Italy.
Luca CimaPathology Unit, Department of Clinical Services, Santa Chiara Hospital, 38100 Trento, Italy.ORCID 0000-0002-3445-1622
Maria Rosaria RaspolliniHistopathology and Molecular Diagnostics, University Hospital Careggi, 50100 Firenze, Italy.ORCID 0000-0001-6630-4881
Mattia BarbareschiPathology Unit, Department of Clinical Services, Santa Chiara Hospital, 38100 Trento, Italy.
Alessandro TafuriDivision of Urology, Department of Surgery, Dentistry, Paediatrics and Gynaecology, University and Hospital Trust of Verona, 37134 Verona, Italy.
Giulia MasiDepartment of Molecular Medicine, University of Padua, 35100 Padova, Italy.
Luisa BarzonDepartment of Molecular Medicine, University of Padua, 35100 Padova, Italy.ORCID 0000-0003-0720-8456
Serena AmmendolaPathology Unit, Department of Diagnostics and Public Health, University and Hospital Trust of Verona, 37134 Verona, Italy.ORCID 0000-0003-1800-0896
Manuela VillanovaPathology Unit, Department of Diagnostics and Public Health, University and Hospital Trust of Verona, 37134 Verona, Italy.
Maria Angela CerrutoDivision of Urology, Department of Surgery, Dentistry, Paediatrics and Gynaecology, University and Hospital Trust of Verona, 37134 Verona, Italy.
Michele MilellaDivision of Oncology, University and Hospital Trust of Verona, 37134 Verona, Italy.
Sebastiano ButiDivision of Oncology, University and Hospital Trust of Parma, 43100 Parma, Italy.ORCID 0000-0003-0876-0226
Melissa BersanelliDivision of Oncology, University and Hospital Trust of Parma, 43100 Parma, Italy.ORCID 0000-0002-6527-6281
Giuseppe FornariniDivision of Oncology, San Martino Hospital, 16100 Genova, Italy.ORCID 0000-0003-4754-6572
Sara Elena RebuzziDivision of Oncology, San Martino Hospital, 16100 Genova, Italy.ORCID 0000-0003-0546-6304
Valerio Gaetano VellonePathology Unit, San Martino Hospital, 16100 Genova, Italy.ORCID 0000-0002-5107-1584
Gabriele GaggeroPathology Unit, San Martino Hospital, 16100 Genova, Italy.
Giuseppe ProcopioDivision of Oncology, IRCCS Foundation, Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy.
Elena VerzoniDivision of Oncology, IRCCS Foundation, Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy.
Sergio BracardaDivision of Oncology, Santa Maria Hospital, 05100 Terni, Italy.
Martina FanelliDivision of Oncology, Department of Oncology, Hematology & Respiratory Diseases, University of Modena & Reggio Emilia, 41121 Modena, Italy.ORCID 0000-0001-9755-0567
Roberto SabbatiniDivision of Oncology, Department of Oncology, Hematology & Respiratory Diseases, University of Modena & Reggio Emilia, 41121 Modena, Italy.ORCID 0000-0002-8943-7545
Rodolfo PassalacquaDivision of Oncology, Hospital Trust of Cremona, 26100 Cremona, Italy.
Bruno PerrucciDivision of Oncology, Hospital Trust of Cremona, 26100 Cremona, Italy.
Maria Olga GigantiDivision of Oncology, Hospital Trust of Cremona, 26100 Cremona, Italy.
Maddalena DoniniDivision of Oncology, Hospital Trust of Cremona, 26100 Cremona, Italy.
Stefano PanniDivision of Oncology, Hospital Trust of Cremona, 26100 Cremona, Italy.
Marcello TucciDivision of Oncology, Cardinal Massaia Hospital, 14100 Asti, Italy.
Veronica PratiDivision of Oncology, Institute for Cancer Research and Treatment, Asl Cn2 Alba-Brà, 12042 Cuneo, Italy.
Cinzia OrtegaDivision of Oncology, Institute for Cancer Research and Treatment, Asl Cn2 Alba-Brà, 12042 Cuneo, Italy.
Anna CaliòPathology Unit, Department of Diagnostics and Public Health, University and Hospital Trust of Verona, 37134 Verona, Italy.
Albino EccherPathology Unit, Department of Diagnostics and Public Health, University and Hospital Trust of Verona, 37134 Verona, Italy.ORCID 0000-0002-9992-5550
Filippo AlongiAdvanced Radiation Oncology Department, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, 37024 Verona, Italy.ORCID 0000-0002-6569-8628
Giovanni PappagalloIndipendent Researcher, Clinical Epidemiologist, Silea, 31057 Treviso, Italy.
Roberto IacovelliPoliclinico Universitario Fondazione Andrea Gemelli, 00168 Roma, Italy.
Alessandra MoscaOncology, Candiolo Cancer Institute, IRCCS-FPO, 10060 Torino, Italy.
Paolo UmariHistopathology and Molecular Diagnostics, University Hospital Careggi, 50100 Firenze, Italy.
Ilaria MontagnaniHistopathology and Molecular Diagnostics, University Hospital Careggi, 50100 Firenze, Italy.
Stefano GobboDepartment of Translation Medicine, Pathology Unit, University of Ferrara, 44100 Ferrara, Italy.ORCID 0000-0001-5247-5233
Francesco AtzoriOncology Unit, University and Hospital Trust of Cagliari, 09100 Cagliari, Italy.ORCID 0000-0002-8211-0363
Enrico MunariPathology Unit, Department of Molecular and Translational Medicine, University of Brescia, 25100 Brescia, Italy.
Marco MaruzzoOncology Unit, Oncology Department, Istituto Oncologico Veneto (IOV), IRCCS, 35128 Padua, Italy.
Umberto BassoOncology Unit, Oncology Department, Istituto Oncologico Veneto (IOV), IRCCS, 35128 Padua, Italy.ORCID 0000-0002-5075-2177
Francesco PiercontiDivision of Pathology, Policlinico Universitario Fondazione Agostino Gemelli, 00168 Roma, Italy.
Carlo PatriarcaPathology Unit, Department of Clinical Services, Sant'Anna Hospital, 22100 Como, Italy.
Piergiuseppe ColomboDepartment of Pathology, Department of Biomedical Sciences, Humanitas University, IRCCS Humanitas Clinical and Research Hospital, Pieve Emanuele, 20089 Milan, Italy.
Alberto LapiniDivision of Urology, University Hospital Careggi, 50100 Firenze, Italy.
Giario ContiDivision of Urology, Sant'Anna Hospital, 22100 Como, Italy.
Roberto SalvioniDepartment of Urology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy.
Enrico BollitoDepartment of Pathology, San Luigi Gonzaga Hospital, University of Turin, 10122 Torino, Italy.
Andrea CossarizzaDepartment of Medical and Surgical Sciences for Children and Adults, University of Modena & Reggio Emilia, 41121 Modena, Italy.ORCID 0000-0002-5381-1558
Francesco MassariMedical Oncology, University and Hospital Trust of Bologna, 40138 Bologna, Italy.
Mimma RizzoDivision of Translational Oncology, IRCCS Istituti Clinici Scientifici 'Maugeri', 27100 Pavia, Italy.
Renato FrancoPathology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania 'Luigi Vanvitelli', 81100 Caserta, Italy.
Federica Zito-MarinoPathology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania 'Luigi Vanvitelli', 81100 Caserta, Italy.
Yoseba Aberasturi PlataDepartment of Pathology, Cruces University Hospital, University of the Basque Country (UPV/EHU), 48900 Barakaldo, Spain.
Francesca GaluppiniDepartment of Pathology, University and Hospital Trust of Padua, 35128 Padova, Italy.ORCID 0000-0002-3245-2322
Marta SbaragliaDepartment of Pathology, University and Hospital Trust of Padua, 35128 Padova, Italy.
Matteo FassanDepartment of Pathology, University and Hospital Trust of Padua, 35128 Padova, Italy.ORCID 0000-0001-6515-5482
Angelo Paolo Dei TosDepartment of Pathology, University and Hospital Trust of Padua, 35128 Padova, Italy.
Maurizio ColecchiaDepartment of Pathology, Uropathology Unit, Vita-Salute San Raffaele University, IRCCS San Raffaele, 20132 Milano, Italy.ORCID 0000-0003-1914-0743
Holger MochDepartment of Pathology and Molecular Pathology, University Hospital Zurich, 8006 Zurich, Switzerland.ORCID 0000-0002-7986-2839
Maurizio ScaltritiAstraZeneca, New York, NY 10005, USA.
Camillo PortaDepartment of Biomedical Sciences and Human Oncology, University of Bari 'A. Moro', 70121 Bari, Italy.ORCID 0000-0003-2412-1563
Brett DelahuntDepartment of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, 3743 Wellington, New Zealand.
Gianluca GiannariniUrology Unit, "Santa Maria della Misericordia", University of Udine, 33100 Udine, Italy.
Roberto BortolusDepartment of Radiotherapy, CRO, 33081 Aviano, Italy.
Pasquale RescignoCandiolo Cancer Institute, FPO-IRCCS, Candiolo, 10060 Turin, Italy.ORCID 0000-0002-4668-4765
Giuseppe Luigi BannaCandiolo Cancer Institute, FPO-IRCCS, Candiolo, 10060 Turin, Italy.
Alessio SignoriDepartment of Health Sciences (DISSAL), Section of Biostatistics, University of Genova, 16100 Genova, Italy.ORCID 0000-0001-6289-9144
Miguel Angel Llaja ObispoMedical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, 16100 Genova, Italy.
Roberto PerrisDepartment of Biosciences, COMT-Centre for Molecular and Translational Oncology, University of Parma, 43124 Parma, Italy.
Alessandro AntonelliDivision of Urology, Department of Surgery, Dentistry, Paediatrics and Gynaecology, University and Hospital Trust of Verona, 37134 Verona, Italy.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to overcome intratumoral heterogeneity in clear cell renal cell carcinoma (clearRCC). One hundred cases of clearRCC were sampled. First, usual standard sampling was applied (1 block/cm of tumor); second, the whole tumor was sampled, and 0.6 mm cores were taken from each block to construct a tissue microarray; third, the residual tissue, mapped by taking pieces 0.5 × 0.5 cm, reconstructed the entire tumor mass. Precisely, six randomly derived pieces of tissues were placed in each cassette, with the number of cassettes being based on the diameter of the tumor (called multisite 3D fusion). Angiogenic and immune markers were tested. Routine 5231 tissue blocks were obtained. Multisite 3D fusion sections showed pattern A, homogeneous high vascular density (10%), pattern B, homogeneous low vascular density (8%) and pattern C, heterogeneous angiogenic signatures (82%). PD-L1 expression was seen as diffuse (7%), low (33%) and absent (60%). Tumor-infiltrating CD8 scored high in 25% (pattern hot), low in 65% (pattern weak) and zero in 10% of cases (pattern desert). Grading was upgraded in 26% of cases (G3-G4), necrosis and sarcomatoid/rhabdoid characters were observed in, respectively, 11 and 7% of cases after 3D fusion (
Indexed as
angiogenesisclear cell renal cell carcinomaimmunityimmunohistochemistryintratumoral heterogeneitytumor sampling
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.